The trials of finding a vaccineDays after Biocon announced an itolizumab drug to treat covid-19 patients, the Indian Council of Medical Research said there is no evidence from clinical trials that either itolizumab and tocilizumab, approved for emergency use, reduce mortality.
It has also come to light that the phase 2 trials only had 31 patients. On the vaccine development front, a number of trials are making progress.
Moderna said its vaccine provoked immune responses in all 45 healthy volunteers in an early-stage US study, pushing its shares up 15%.
In Russia, all 18 volunteers in a vaccine trial were discharged after a 28-day observation period. The defence ministry said the initial phase was a “success".